stoxline Quote Chart Rank Option Currency Glossary
  
Xeris Biopharma Holdings, Inc. (XERS)
2.24  -0.06 (-2.61%)    06-12 16:00
Open: 2.33
High: 2.38
Volume: 1,337,783
  
Pre. Close: 2.3
Low: 2.22
Market Cap: 332(M)
Technical analysis
2024-06-12 4:26:05 PM
Short term     
Mid term     
Targets 6-month :  2.93 1-year :  3.42
Resists First :  2.5 Second :  2.93
Pivot price 2.19
Supports First :  2.02 Second :  1.72
MAs MA(5) :  2.3 MA(20) :  2.15
MA(100) :  2.27 MA(250) :  2.2
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  65.6 D(3) :  69.7
RSI RSI(14): 56.3
52-week High :  3.25 Low :  1.46
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XERS ] has closed below upper band by 44.4%. Bollinger Bands are 22.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.4 - 2.42 2.42 - 2.43
Low: 2.17 - 2.2 2.2 - 2.22
Close: 2.21 - 2.25 2.25 - 2.28
Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Headline News

Tue, 11 Jun 2024
Invenomic Capital Management LP Acquires Shares of 568,619 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat

Thu, 06 Jun 2024
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit - Yahoo Finance

Tue, 04 Jun 2024
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company - Simply Wall St

Fri, 31 May 2024
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) surges 15%; individual investors who own 54% shares profited along with institutions - Simply Wall St

Thu, 30 May 2024
Xeris to Participate in the Jefferies Global Healthcare Conference - Business Wire

Sun, 26 May 2024
Panagora Asset Management Inc. Cuts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 148 (M)
Shares Float 144 (M)
Held by Insiders 2.6 (%)
Held by Institutions 42.7 (%)
Shares Short 10,790 (K)
Shares Short P.Month 8,940 (K)
Stock Financials
EPS -0.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.06
Profit Margin -37.6 %
Operating Margin -35.1 %
Return on Assets (ttm) -8.6 %
Return on Equity (ttm) -617.2 %
Qtrly Rev. Growth 22.3 %
Gross Profit (p.s.) 0
Sales Per Share 1.15
EBITDA (p.s.) -0.23
Qtrly Earnings Growth 0 %
Operating Cash Flow -41 (M)
Levered Free Cash Flow -47 (M)
Stock Valuations
PE Ratio -4.77
PEG Ratio 0
Price to Book value -37.34
Price to Sales 1.93
Price to Cash Flow -8.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android